Pharma & Biotech

Cellectis plans to submit a Biologics License Application for lasme-cel to the FDA in 2028, targeting a leukemia treatment market the company projects could reach $700M in peak sales by 2035. The Paris-based biotech reported $225M in cash reserves as of September 30, 2025, funding operations into the second half of 2027. The regulatory milestone comes as Cellectis posted $62.6M in nine-month revenues, more than double the prior year period.

GSK is targeting a late 2027 commercial launch for depemokimab, an ultra-long-acting biologic designed to treat severe eosinophilic asthma and other inflammatory conditions. The drug represents a significant R&D investment in next-generation biologics that could command premium pricing in a global asthma therapeutics market projected to exceed $164 billion. For investors, the timeline signals a near-term catalyst in GSK's pipeline that warrants close attention.